Utpal Koppikar
Director/Board Member chez C4 THERAPEUTICS, INC.
Fortune : 172 592 $ au 31/03/2024
Profil
Utpal Koppikar is an Independent Director at C4 Therapeutics, Inc. He previously worked as a Director at Flexion Therapeutics, Inc. and as Vice President-Corporate & Operations Finance at Gilead Sciences, Inc. He is also the Chief Financial Officer & Senior Vice President at Atara Biotherapeutics, Inc. Mr. Koppikar holds a graduate degree from Stanford University, an undergraduate degree from the University of Maryland, and an MBA from UCLA Anderson School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 02/03/2023 | 181 978 ( 0,14% ) | 126 293 $ | 31/03/2024 | |
C4 THERAPEUTICS, INC.
0,01% | 15/06/2023 | 5 667 ( 0,01% ) | 46 299 $ | 31/03/2024 |
Postes actifs de Utpal Koppikar
| Sociétés | Poste | Début |
|---|---|---|
| C4 THERAPEUTICS, INC. | Director/Board Member | 16/03/2022 |
Anciens postes connus de Utpal Koppikar
| Sociétés | Poste | Fin |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Director of Finance/CFO | 31/03/2023 |
| FLEXION THERAPEUTICS, INC. | Director/Board Member | 19/11/2021 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/06/2018 |
Formation de Utpal Koppikar
| Stanford University | Graduate Degree |
| University of Maryland | Undergraduate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| C4 THERAPEUTICS, INC. | Health Technology |
| ATARA BIOTHERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
